|
15-07-2008
: |
Jubilant Organosys Reports Q1 FY09 Revenues growth of 53% to Rs. 826.6 crore; Pharma & Life Science revenues increase 72%; Q1 FY09 EBITDA increases 62% to Rs. 173.2 crore. |
|
Revenues for 1st quarter ended June 30, 2008 rose by 53.1% to Rs. 826.6 crore over Q1 FY 2008. The international revenue was also higher by 74% at Rs. 484.6 crore on account of volume growth in the outsourcing related segments comprising CRAMS and DDDS.
|
|
14-07-2008
: |
Jubilant in Drug Discovery partnership with Amgen Inc, USA |
|
Jubilant Biosys Ltd and Amgen Inc, the largest US based Biotech company have announced a drug discovery partnership under which Amgen and Jubilant will collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas.
|
|
29-05-2008
: |
Jubilant successfully completes acquisition of Draxis for US$ 253 million |
|
Jubilant Organosys Ltd., (Jubilant) an integrated pharmaceutical industry player and India's largest Custom Research and Manufacturing Services (CRAMS) Company announced today that it had completed the transaction effective May 28, 2008, to acquire Canada based Draxis Speciality Pharmaceuticals Inc. (Draxis).
|
|
08-05-2008
: |
Jubilant acquires Speciality Molecules Pvt. Ltd., India |
|
Jubilant Organosys Ltd., has announced that it had acquired Speciality Molecules Pvt. Ltd., a niche manufacturer of Speciality Intermediates with manufacturing facilities located in Ambarnath (near Mumbai) in India.
|
|
22-04-2008
: |
Q4 FY08 Revenues grown 49% to Rs. 6,890 million; Net Profit at Rs. 582 million |
|
FY08 Revenues improved 38% to Rs. 24,889 million; PAT up 76% at Rs. 4,005 million
Board declares increased dividend at 150% for the year
|
|
04-04-2008
: |
Jubilant to acquire Draxis Health |
|
Jubilant Organosys Ltd. and DRAXIS Health Inc. today announced that they have entered into an arrangement agreement whereby a wholly-owned subsidiary of Jubilant Organosys Ltd. will acquire all the outstanding common shares of DRAXIS at a price of US$6.00 per share in cash by way of a plan of arrangement. The total value of this transaction is approximately US$255 million.
|
| 9-10-2007 : |
Clinsys Clinical Research, Inc., announces key hires |
|
Rajagopalan Srinivasan, Ph.D, as Vice Preseident, Global Biostatistics and Christopher Gregory, Ph.D as Scientific Affairs - Director
|
| 9-10-2007 : |
Clinsys Clinical Research, Inc., announces relocation of corporate headquarters
|
|
Relocation of headquarters done to accommodate the company's significant growth and plans for future expansion. The new, larger facility is located in Bedminster, New Jersey
|
| 9-10-2007 : |
Clinsys Clinical Research, Inc., and ITEC Services establish strategic alliance to expand CRO offerings Globally
|
|
The alliance will enable Clinsys to extend its global clinical operations and consulting services in Europe and North Africa
|
| |
|
|
| |
Archives |
|
